Search results for "Terbutaline"

showing 7 items of 7 documents

The novel combination of theophylline and bambuterol as a potential treatment of hypoxemia in humans.

2017

Hypoxemia can be life-threatening, both acutely and chronically. Because hypoxemia causes vascular dysregulation that further restricts oxygen availability to tissue, it can be pharmacologically addressed. We hypothesized that theophylline can be safely combined with the β2-adrenergic vasodilator bambuterol to improve oxygen availability in hypoxemic patients. Ergogenicity and hemodynamic effects of bambuterol and theophylline were measured in rats under hypobaric and normobaric hypoxia (12% O2). Feasibility in humans was assessed using randomized, double-blind testing of the influence of combined slow-release theophylline (300 mg) and bambuterol (20 mg) on adverse events (AEs), plasma K+,…

AdultMaleCombination therapyPhysiologyAdrenergicBiological Availability030204 cardiovascular system & hematologyPharmacologyHypoxemia03 medical and health sciencesYoung Adult0302 clinical medicineTheophyllinePhysiology (medical)Physical Conditioning AnimalmedicineTerbutalineAnimalsHumansTheophyllineDrug InteractionsBambuterolHypoxiaPharmacologybusiness.industryHemodynamicsGeneral MedicineDrug interactionHypoxia (medical)RatsBlood pressureTreatment OutcomeAnesthesiaFemalemedicine.symptomSafetybusiness030217 neurology & neurosurgerymedicine.drugHalf-LifeCanadian journal of physiology and pharmacology
researchProduct

Influence of low temperature on bronchodilatation induced by terbutaline administered by metered dose or dry powder inhalers in asthmatics.

2000

Low temperatures may affect dose delivery efficacy and clinical effectiveness of medication aerosols. In this study we examine the effect of cold ambient temperature on the bronchodilatation produced by terbutaline delivered from a chlorofluorocarbon pressurized metered dose inhaler (pMDI) compared to a multi-dose dry powder inhaler (DPI). Fourteen stable asthmatics were studied on two consecutive days. On day 1, after measuring FEV1 at room temperature (22 degrees C), each patient was randomized to receive 500 microg of terbutaline delivered from pMDI or DPI stored for 24 h at 22 degrees C with FEV1 recorded 20 min post-dose; then, patients were placed in a chamber at -10 degrees C, and af…

AdultMalemedicine.drug_classTerbutalineCold storageBronchiBronchodilatorForced Expiratory VolumeAdministration InhalationmedicineTerbutalineHumansPharmacology (medical)PharmacologyDose-Response Relationship DrugCumulative doseChemistryInhalerAdrenergic beta-AgonistsMiddle AgedMetered-dose inhalerDry-powder inhalerAsthmaBronchodilator AgentsCold TemperatureBronchodilatationAnesthesiaFemalePowdersmedicine.drugFundamentalclinical pharmacology
researchProduct

Sources of human plasma cyclic AMP. Examinations before and after beta 2 adrenergic stimulation.

1981

Plasma cyclic AMP was measured in different vessels in seventeen volunteers before and after stimulation with terbutaline. Differences between arterial blood and blood from the hepatic vein, right ventricle, inferior vena cava and a cubital vein could not be demonstrated. Only in the renal vein was the concentration of cyclic AMP decreased. Our results indicate that cyclic AMP is not generated from any specific isolated organ and that changes in cyclic AMP after subcutaneous injection of terbutaline reflect a general influence of this drug.

AdultMalemedicine.medical_specialtyInjections SubcutaneousTerbutalineStimulation030204 cardiovascular system & hematology030226 pharmacology & pharmacyBiochemistryInferior vena cava03 medical and health sciences0302 clinical medicineAdrenergic stimulationInternal medicineCyclic AMPTerbutalineMedicineHumansVeinAgedbusiness.industryBiochemistry (medical)Cell BiologyGeneral MedicineAdrenergic beta-AgonistsMiddle AgedStimulation Chemicalmedicine.anatomical_structureEndocrinologymedicine.veinVentriclecardiovascular systemArterial bloodRenal veinbusinessmedicine.drugThe Journal of international medical research
researchProduct

Progesterone increases basal 3',5'-cyclic adenosine monophosphate formation and down-regulates the agonist-induced inositol phosphates generation in …

1992

Whether the placenta is a target tissue for estrogens and progesterone, and their putative mechanism of action, is still a controversial question in the literature. The effect of progesterone and estradiol on 3′,5′-cyclic adenosine monophosphate (cAMP) and inositol phosphates generation in human term placenta was investigated. Placental explants were incubated in vitro for up to 48 h in the absence and in the presence of estradiol, progesterone or both steroids (0.1 μmol/l final concentration in all cases), and were stimulated with terbutaline, a β-adrenergic agonist, (0.1 mmol/l) or angiotensin II(1 μmol/l), The cAMP content was measured by a competitive protein binding assay, and the gene…

Agonistmedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismInositol PhosphatesPlacentaDown-RegulationBiologychemistry.chemical_compoundEndocrinologyPregnancyInternal medicinePlacentamedicineCyclic AMPTerbutalineHumansCyclic adenosine monophosphateInositolInositol phosphateProgesteronechemistry.chemical_classificationLabor ObstetricEstradiolAngiotensin IIGeneral MedicineTrypan BlueChromatography Ion ExchangeAngiotensin IIEndocrinologymedicine.anatomical_structurechemistryEstrogenSecond messenger systemLactatesFemaleActa endocrinologica
researchProduct

Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: A non-inferiority, randomised, double-blind clinical tr…

2015

Summary Background Treatment guidelines for patients with moderate persistent asthma recommend regular therapy with a combination of an inhaled corticosteroid and a longacting β 2 agonist plus as-needed rapid-acting bronchodilators. We investigated whether symptom-driven budesonide and formoterol combination therapy administered as needed would be as effective as regular treatment with this combination plus as-needed symptom-driven terbutaline for patients with moderate asthma. Methods In this non-inferiority randomised clinical trial, we recruited adult patients (18–65 years of age) with stable moderate persistent asthma, according to 2006 Global Initiative for Asthma guidelines. Patients …

BudesonideMalePediatricsKaplan-Meier Estimatelaw.inventionRandomized controlled triallawMedicineOutpatient clinicBudesonide Formoterol Fumarate Drug CombinationAnti-Asthmatic AgentsTreatment Failureeducation.field_of_studyasthma; clinical trialMedicine (all)clinical trialMiddle AgedCombined Modality TherapyBronchodilator AgentsFemalemedicine.drugHumanAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentTerbutalinePopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioPlaceboDrug Administration ScheduleNOYoung AdultDouble-Blind MethodAdministration InhalationTerbutalineinhaled corticosteroids LABA asthma clinical trialHumansAnti-Asthmatic AgenteducationBronchodilator AgentPulmonary and Respiratory Medicine; Medicine (all)AsthmaAgedPulmonary and Respiratory Medicine RCT asthmabusiness.industryComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKSmedicine.diseaseAsthmarespiratory tract diseasesFormoterolbusiness
researchProduct

Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations

2007

This randomised, double-blind, 6-month study compared budesonide/formoterol for maintenance and relief with salmeterol/fluticasone and a fixed maintenance dose of budesonide/formoterol, both with terbutaline for relief. Following a 2-week run-in, 3335 symptomatic adults and adolescents (mean FEV1 73% predicted, mean inhaled corticosteroid dose 745 μg/day) received budesonide/formoterol 160/4.5 μg one inhalation bid plus additional inhalations as needed, salmeterol/fluticasone 25/125 μg two inhalations bid plus as-needed terbutaline or budesonide/formoterol 320/9 μg one inhalation bid plus as-needed terbutaline. Budesonide/formoterol for maintenance and relief prolonged the time to first sev…

Budesonidemedicine.drug_classbusiness.industryTerbutalineGeneral Medicinerespiratory systemrespiratory tract diseasesBudesonide/formoterolimmune system diseasesBronchodilatorAnesthesiamedicineFormoterol FumarateFormoterolSalmeterolbusinesshormones hormone substitutes and hormone antagonistscirculatory and respiratory physiologymedicine.drugFluticasoneInternational Journal of Clinical Practice
researchProduct

Functional, biochemical and molecular biological evidence for a possible β3-adrenoceptor in human near-term myometrium

2000

The possible existence of a β3-adrenoceptor (β3-AR) in human near-term myometrium was investigated by in vitro functional and biochemical studies and analysis of mRNA expression. SR 59119A and SR 59104A and CGP 12177 (two selective agonists and a partial agonist, respectively, of the β3-AR), salbutamol and terbutaline (β2-AR agonists) each produced a concentration-dependent relaxation of the myometrial spontaneous contractions. There were no differences in pD2 values for the relaxing potencies of terbutaline, salbutamol, CGP 12177 and SR 59119A. The rank order for their relaxing efficacies was SR 59119A>SR 59104A>terbutaline∼salbutamol∼CGP 12177 (Emax=52±7%, 42±12% and ∼ 30% respectively). …

PharmacologyAgonistmedicine.medical_specialtymedicine.drug_classTerbutalineMyometriumAntagonistPropranololBiologyPartial agonistMuscle relaxationEndocrinologyMechanism of actionInternal medicinemedicinemedicine.symptommedicine.drugBritish Journal of Pharmacology
researchProduct